New hope for Alzheimer’s treatment: Biogen and Eisai report promising results from Phase II Clinical Study of BAN2401
New data presented at the Alzheimer’s Association International Conference on July 25th came as an unexpected surprise. Patients receiving the drug performed 30 percent better on cognitive tests than those